Core Viewpoint - The company, Shandong Weigao Blood Purification Products Co., Ltd., is actively expanding its overseas business and is involved in a significant asset restructuring transaction to acquire 100% equity of Weigao Puri Pharmaceutical Packaging Co., Ltd. [2][3] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [2][3][7] - The company was established on December 27, 2004, and went public on May 19, 2025 [3][7] - As of September 30, the company had 24,800 shareholders, a decrease of 20.95% from the previous period, with an average of 1,535 circulating shares per person, an increase of 26.51% [7] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 2.736 billion yuan, representing a year-on-year growth of 3.45% [8] - The net profit attributable to the parent company was 341 million yuan, reflecting a year-on-year increase of 7.92% [8] - The company's main business revenue composition includes consumables at 77.55%, equipment at 18.25%, and other categories at 4.2% [7] Market Activity - On December 5, the stock price of Weigao Blood Purification increased by 0.34%, with a trading volume of 84.58 million yuan and a turnover rate of 5.27%, resulting in a total market capitalization of 17.199 billion yuan [1] - The stock has seen a net outflow of 9.19 million yuan from major investors today, with a total net outflow of 179 million yuan over the past 20 days [5]
威高血净涨0.34%，成交额8457.99万元，后市是否有机会？